Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?
Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(14), 4821; https://doi.org/10.3390/ijms21144821
Received: 15 June 2020
/
Revised: 2 July 2020
/
Accepted: 6 July 2020
/
Published: 8 July 2020
(This article belongs to the Special Issue Adenovirus: Enduring Toolbox for Basic and Applied Research)
Non-human primate (NHP)-derived adenoviruses have formed a valuable alternative for the use of human adenoviruses in vaccine development and gene therapy strategies by virtue of the low seroprevalence of neutralizing immunity in the human population. The more recent use of several human adenoviruses as oncolytic agents has exhibited excellent safety profiles and firm evidence of clinical efficacy. This proffers the question whether NHP-derived adenoviruses could also be employed for viral oncolysis in human patients. While vaccine vectors are conventionally made as replication-defective vectors, in oncolytic applications replication-competent viruses are used. The data on NHP-derived adenoviral vectors obtained from vaccination studies can only partially support the suitability of NHP-derived adenoviruses for use in oncolytic virus therapy. In addition, the use of NHP-derived adenoviruses in humans might be received warily given the recent zoonotic infections with influenza viruses and coronaviruses. In this review, we discuss the similarities and differences between human- and NHP-derived adenoviruses in view of their use as oncolytic agents. These include their genome organization, receptor use, replication and cell lysis, modulation of the host’s immune responses, as well as their pathogenicity in humans. Together, the data should facilitate a rational and data-supported decision on the suitability of NHP-derived adenoviruses for prospective use in oncolytic virus therapy.
View Full-Text
Keywords:
non-human primate adenovirus; human adenovirus; oncolytic virus; adenoviral vector; taxonomy; genetic recombination; oncolysis; anti-tumor immunity
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 618 KiB)
MDPI and ACS Style
Bots, S.T.F.; Hoeben, R.C. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents? Int. J. Mol. Sci. 2020, 21, 4821. https://doi.org/10.3390/ijms21144821
AMA Style
Bots STF, Hoeben RC. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents? International Journal of Molecular Sciences. 2020; 21(14):4821. https://doi.org/10.3390/ijms21144821
Chicago/Turabian StyleBots, Selas T.F., and Rob C. Hoeben. 2020. "Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?" International Journal of Molecular Sciences 21, no. 14: 4821. https://doi.org/10.3390/ijms21144821
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
